Assuntos
Artrite/genética , Antígenos HLA-A/genética , Antígenos HLA-B/genética , Sarcoidose/genética , Feminino , Humanos , MasculinoAssuntos
Aneurisma Aórtico/epidemiologia , Arteriopatias Oclusivas/epidemiologia , Biópsia , Doença da Artéria Coronariana/epidemiologia , Arterite de Células Gigantes/epidemiologia , Trombose/epidemiologia , Aneurisma Aórtico/mortalidade , Arteriopatias Oclusivas/mortalidade , Doença da Artéria Coronariana/mortalidade , Arterite de Células Gigantes/mortalidade , Arterite de Células Gigantes/patologia , Humanos , Valor Preditivo dos Testes , Prognóstico , Medição de Risco , Fatores de Risco , Trombose/mortalidadeAssuntos
Humanos , Masculino , Pessoa de Meia-Idade , Eritema Nodoso/diagnóstico , Eritema Nodoso/tratamento farmacológico , Eritema Nodoso/etiologia , Hepatite B/complicações , Hepatite B/etiologia , Leucemia/complicações , Leucemia/diagnóstico , Antirretrovirais/uso terapêutico , Eritema Nodoso/fisiopatologia , Leucemia/fisiopatologia , Radiografia Torácica , Citometria de Fluxo , Sarcoidose/complicações , Sarcoidose/etiologia , Sarcoidose/terapiaRESUMO
OBJECTIVE: To assess whether polymorphism of the interleukin (IL)-6 gene at the position -174 was implicated in the incidence of Henoch-Schönlein pur-pura (HSP). A further objective was to determine if any relationship existed with severe systemic complications of HSP, in particular with severe renal and gastrointestinal involvement. METHODS: Unselected patients from Northwest Spain with primary cutaneous vasculitis classified as HSP according to proposed criteria were studied. All patients included in the present study were required to have had at least 2 year's follow-up. Patients and controls were genotyped for a single biallelic (G/C) nucleotide polymorphism in the promoter region at the position -174 of the IL-6 gene by a polymerase reaction chain-restriction fragment length polymorphism (PCR-RFLP) method. RESULTS: Forty-six Caucasian HSP patients and 124 healthy matched controls were studied. No allele or genotype differences between the whole group of HSP and controls were observed. This was also the case when HSP patients were stratified by the presence of gastrointestinal complications, nephritis, and permanent renal involvement (renal sequelae). CONCLUSION: The polymorphism in IL-6 gene promoter (-174 G/C) does not appear to be a genetic risk factor for HSP in Northwest Spain.
Assuntos
Predisposição Genética para Doença , Vasculite por IgA/genética , Interleucina-6/genética , Polimorfismo de Fragmento de Restrição , Polimorfismo de Nucleotídeo Único , Adolescente , Adulto , Idade de Início , Criança , Pré-Escolar , Comorbidade , Impressões Digitais de DNA , Feminino , Gastroenteropatias/epidemiologia , Gastroenteropatias/genética , Gastroenteropatias/patologia , Frequência do Gene , Genótipo , Humanos , Vasculite por IgA/epidemiologia , Vasculite por IgA/patologia , Artropatias/epidemiologia , Artropatias/genética , Artropatias/patologia , Nefropatias/epidemiologia , Nefropatias/genética , Nefropatias/patologia , Masculino , Pessoa de Meia-Idade , Regiões Promotoras Genéticas , Fatores de Risco , Espanha/epidemiologiaRESUMO
OBJECTIVE: The aim of this study was to assess the potential contribution of HLA-class I MICA and HLA-B gene polymorphisms towards the pathogenesis of giant cell arteritis (GCA). METHODS: Ninety-eight biopsy-proven GCA patients and 225 ethnically matched controls from Lugo, Northwest Spain, were genotyped for the MICA-TM microsatellite polymorphism using a polymerase chain reaction (PCR)-based method. Genotyping of HLA-B was performed using PCR and detection with a reverse sequence-specific oligonucleotide (SSO) probes system. RESULTS: A significant difference in the distribution of the alleles of MICA between patient and control groups (P = 0.005) was found. This was due to an increased frequency of the MICA A5 allele in GCA patients compared with controls (26 vs 13.6%; P = 0.0001; P(C) = 0.0005; OR 2.2, 95% CI 1.4-3.4). In addition, the HLA-B*15 allele showed a higher frequency in GCA patients compared with controls (P = 0.004; P(C) = 0.04; OR 2.7, 95% CI 1.3-5.7). Interestingly, the association observed with the MICA A5 allele seems to be independent of linkage disequilibrium with HLA-B, as well as independent of that previously described with HLA-DRB1*04. Remarkably, simultaneous presence of MICA A5 and HLA-B*15 or HLA-DRB1*04 genetic markers leads to an increase in the OR obtained for each individual genetic marker (MICA A5 + B*15 OR 3.2; MICA A5 + DRB1*04 OR 5.8). CONCLUSIONS: Our results provide the first evidence that the MICA and HLA-B genes are independently associated with the genetic susceptibility to GCA, and suggest that several genes within the MHC might have independent effects in the susceptibility to this systemic vasculitis.
Assuntos
Genes MHC Classe I , Predisposição Genética para Doença , Arterite de Células Gigantes/genética , Idoso , Idoso de 80 Anos ou mais , Feminino , Frequência do Gene , Genótipo , Antígenos HLA-B/genética , Antígeno HLA-B15 , Antígenos HLA-DR/genética , Cadeias HLA-DRB1 , Antígenos de Histocompatibilidade Classe I/genética , Humanos , Masculino , Repetições de Microssatélites/genética , Pessoa de Meia-IdadeRESUMO
OBJECTIVE: To assess whether polymorphism of the macrophage migration inhibitory factor (MIF) gene at position -173 was implicated in the incidence of Henoch-Schönlein purpura (HSP) and cutaneous leukocytoclastic angiitis (CLA). A further objective was to determine if any relationship existed with severe systemic complications of HSP, in particular with severe renal involvement and permanent renal dysfunction. METHODS: Unselected patients from Northwest Spain with primary cutaneous vasculitis classified as HSP or hypersensitivity vasculitis (HV) according to proposed criteria were studied. Patients with HV were included in this study if they fulfilled the Chapel Hill Consensus Conference on the Nomenclature of Systemic Vasculitis definitions for CLA. Patients and controls were genotyped for a single nucleotide polymorphism (SNP) in the 5'-flanking region at position -173 of the MIF gene, using SNapshot ddNTP primer extension, followed by capillary electrophoresis (ABI 3100). RESULTS: Ninety-five Caucasian patients (57 classified as having HSP and 38 who fulfilled definitions for CLA) and 122 healthy controls were studied. No allele or genotype differences between the whole group of HSP or CLA patients and controls were observed. This was also the case when HSP patients were stratified by the presence of gastrointestinal complications, nephritis, and permanent renal involvement (renal sequelae). CONCLUSION: The polymorphism in MIF gene promoter (-173 G/C) does not appear to be genetic risk factors for cutaneous vasculitis in Northwest Spain.
Assuntos
Predisposição Genética para Doença , Vasculite por IgA/genética , Fatores Inibidores da Migração de Macrófagos/genética , Polimorfismo Genético , Vasculite Leucocitoclástica Cutânea/genética , Adolescente , Adulto , Idoso , Criança , Pré-Escolar , Feminino , Frequência do Gene , Genótipo , Humanos , Vasculite por IgA/complicações , Vasculite por IgA/patologia , Rim/patologia , Nefropatias/complicações , Nefropatias/patologia , Fatores Inibidores da Migração de Macrófagos/metabolismo , Masculino , Pessoa de Meia-Idade , Vasculite Leucocitoclástica Cutânea/complicações , Vasculite Leucocitoclástica Cutânea/patologiaAssuntos
Actinobacteria/isolamento & purificação , Derrame Pleural/patologia , Doença de Whipple/diagnóstico , Actinobacteria/genética , Adulto , Anti-Infecciosos/uso terapêutico , DNA Bacteriano/análise , Duodeno/microbiologia , Duodeno/patologia , Humanos , Masculino , Derrame Pleural/etiologia , Derrame Pleural/microbiologia , Reação em Cadeia da Polimerase/métodos , RNA Bacteriano/análise , RNA Ribossômico 16S/análise , Radiografia Torácica , Combinação Trimetoprima e Sulfametoxazol/uso terapêutico , Doença de Whipple/complicações , Doença de Whipple/tratamento farmacológico , Doença de Whipple/microbiologiaRESUMO
OBJECTIVE: Chronic systemic inflammation plays a pivotal role in the development of atherosclerosis in rheumatoid arthritis (RA). Soluble (s) adhesion molecules were found significantly increased in RA patients with active disease. Since increased levels of some adhesion molecules were closely linked to the development of endothelial dysfunction and atherosclerosis and administration of anti-TNF-alpha-infliximab resulted in a rapid and dramatic improvement of endothelial function in long-term infliximab treated RA patients, we assessed whether infusion of the chimeric anti-TNF-alpha infliximab might also yield a rapid and favorable effect on serum levels of soluble adhesion molecules in RA patients periodically treated with this drug because of severe disease. METHODS: We recruited patients with RA refractory to conventional therapy seen over a period of 2 months at Hospital Xeral-Calde, Lugo, Spain, who were on periodical treatment with infliximab for at least 14 weeks. Blood samples for determination of sICAM-1, sICAM-3, sVCAM-1, sE-selectin, and sP-selectin levels by ELISA were taken immediately before and after infliximab infusion. RESULTS: Thirty-four RA patients (25 women; mean age: 55.4 years; mean DAS28: 4.27) fulfilled the inclusion criteria. Following infliximab infusion a reduction of the overall mean values of the five adhesion molecules was observed. However, when a Wilcoxon signed-rank test was used, only significant differences for sICAM-3 and sP-selectin were observed. In this regard, sICAM-3 and sP-selectin levels fell in 26 (77%) and 28 (82%) of the 34 patients. CONCLUSION: Our study confirms a rapid and beneficial effect of infliximab infusion on expression of some adhesion molecules in RA patients treated periodically with this anti-TNF-alpha monoclonal antibody because of severe disease.
Assuntos
Anticorpos Monoclonais/uso terapêutico , Antirreumáticos/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Aterosclerose/metabolismo , Moléculas de Adesão Celular/sangue , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Adulto , Idoso , Artrite Reumatoide/sangue , Artrite Reumatoide/fisiopatologia , Aterosclerose/prevenção & controle , Endotélio Vascular/efeitos dos fármacos , Endotélio Vascular/metabolismo , Ensaio de Imunoadsorção Enzimática , Feminino , Humanos , Infliximab , Masculino , Pessoa de Meia-Idade , Índice de Gravidade de Doença , Falha de TratamentoRESUMO
OBJECTIVE: Endothelial dysfunction has been found in patients with rheumatoid arthritis (RA). In this study we aimed to assess whether adalimumab, a fully human monoclonal antibody directed against TNF-alpha, was able to improve endothelial function in RA patients with long-standing disease refractory to infliximab. METHODS: Eight RA patients (7 women; range: 24- 74 years) were studied. They had been treated with the chimeric monoclonal anti-TNF-alpha antibody-infliximab for at least 1 year and were switched to adalimumab therapy because of loss of efficacy following periodical treatment with infliximab. Endothelial dependent (EDV) and independent vasodilatation (EIV) were measured by brachial ultrasonography. Patients were assessed prior to (day 0) and at day 2, and weeks 2 and 12 after the onset of adalimumab therapy. RESULTS: Following adalimumab administration a rapid increase in the percentage (%) of EDV was found in all patients (mean +/- SD: 10.1 +/- 5.1% at day 2 compared to 5.8 +/- 4.1% at day 0). At weeks 2 and 12 the %EDV was also significantly increased compared to day 0. All patients showed decrease in the disease activity score 28 and C-reactive protein levels (P = 0.012). Moreover, at week 12 the atherogenic index was reduced in all patients (P = 0.012). CONCLUSION: Our study confirms that short-term adalimumab therapy yields an active and positive effect on endothelial function in long-standing RA patients with severe disease. This observation emphasizes the potential role of the TNF-alpha blockade in the mechanisms implicated in the development of atherogenesis in RA.
Assuntos
Anticorpos Monoclonais/farmacologia , Antirreumáticos/farmacologia , Artrite Reumatoide/patologia , Endotélio Vascular/efeitos dos fármacos , Adalimumab , Adulto , Idoso , Anticorpos Monoclonais/uso terapêutico , Anticorpos Monoclonais Humanizados , Antirreumáticos/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Artéria Braquial/diagnóstico por imagem , Artéria Braquial/efeitos dos fármacos , Artéria Braquial/fisiopatologia , Endotélio Vascular/fisiopatologia , Feminino , Humanos , Infliximab , Masculino , Pessoa de Meia-Idade , Falha de Tratamento , Ultrassonografia , Vasodilatação/efeitos dos fármacosAssuntos
Arteriopatias Oclusivas/etiologia , Arterite de Células Gigantes/complicações , Insuficiência Vertebrobasilar/etiologia , Idoso , Arteriopatias Oclusivas/complicações , Biópsia , Arterite de Células Gigantes/patologia , Humanos , Imageamento por Ressonância Magnética , Masculino , Acidente Vascular Cerebral/etiologia , Acidente Vascular Cerebral/patologia , Artérias Temporais/patologia , Insuficiência Vertebrobasilar/complicações , Insuficiência Vertebrobasilar/patologiaRESUMO
OBJECTIVE: Systemic inflammation, insulin resistance, and endothelial dysfunction have been implicated in the development of cardiovascular disease in rheumatoid arthritis (RA). Since insulin resistance can promote endothelial dysfunction and anti-TNF-alpha blockade yield a rapid improvement of endothelial function, we have sought to assess whether TNF-alpha blockade may also result in a reduction of insulin serum levels and improvement of insulin resistance in RA patients who require this therapy because of severe and refractory disease. METHODS: We recruited patients with RA seen over a period of 1 month at Hospital Xeral-Calde, Lugo, Spain, that were on treatment with anti-TNF-alpha monoclonal antibody-infliximab. Patients with diabetes mellitus or plasma glucose > 110 mg/dl were excluded. Fasting blood samples were taken for determination of plasma glucose and serum insulin levels immediately prior to and after infliximab infusion. RESULTS: Twenty-seven RA patients (21 women; mean age: 57.1 years; mean DAS28: 4.43) fulfilled the inclusion criteria. Dramatic reduction in the serum insulin levels and insulin/glucose index was observed following infliximab infusion. Also, a significant improvement of insulin resistance and insulin sensitivity was found. CONCLUSION: Our study confirms a rapid beneficial effect of infliximab on insulin resistance and insulin sensitivity in RA patients treated periodically with this drug. It may support the long-term use of drugs that act blocking TNF-alpha function to reduce the mechanisms implicated in the development of atherosclerosis in patients with RA.
Assuntos
Anticorpos Monoclonais/uso terapêutico , Antirreumáticos/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Resistência à Insulina , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Adulto , Idoso , Artrite Reumatoide/sangue , Glicemia/análise , Quimioterapia Combinada , Feminino , Humanos , Infliximab , Insulina/sangue , Masculino , Pessoa de Meia-Idade , Resultado do TratamentoRESUMO
Secondary vasculitis resulting from unusual pathologic expressions of infections has been described and has important clinical significance. Infectious agents have also been implicated in the pathogenesis of different primary systemic necrotizing vasculitides. Infectious endocarditis is of particular importance in the differential diagnosis of a patient presenting with ANCA associated vasculitis. We report a well-documented case of a patient with recurrent Staphylococcus aureus bacteremia who developed bacterial endocarditis and also fulfilled the Chapel Hill Conference definitions for microscopic polyangiitis. To the best of our knowledge, it is the second case of bacterial endocarditis associated with both pANCA and anti-MPO specificity that fulfilled definitions for systemic necrotizing vasculitis. We emphasize the potential pathogenic role of infection as the trigger factor for the development of systemic vasculitis.
Assuntos
Bacteriemia/microbiologia , Endocardite Bacteriana/complicações , Infecções Estafilocócicas/complicações , Vasculite/etiologia , Idoso , Anticorpos Anticitoplasma de Neutrófilos/fisiologia , Feminino , Humanos , Recidiva , Staphylococcus aureus/isolamento & purificação , Vasculite/diagnósticoRESUMO
No disponible
No disponible
Assuntos
Humanos , Arterite de Células Gigantes/complicações , Arterite de Células Gigantes/diagnóstico , Arterite de Células Gigantes/prevenção & controle , Acidente Vascular Cerebral/etiologia , Anemia/sangue , Aneurisma/etiologia , Estudos Epidemiológicos , InflamaçãoAssuntos
Transtornos Cerebrovasculares/etiologia , Arterite de Células Gigantes/complicações , Arterite de Células Gigantes/diagnóstico , Transtornos Cerebrovasculares/diagnóstico , Transtornos Cerebrovasculares/prevenção & controle , Humanos , Pessoa de Meia-Idade , Estudos Retrospectivos , Fatores de RiscoRESUMO
OBJECTIVE: To assess the influence of inducible and endothelial nitric oxide synthase (iNOS and eNOS) polymorphisms in susceptibility to rheumatoid arthritis (RA). METHODS: Two hundred RA patients fulfilling the 1987 American College of Rheumatology classification criteria followed at the out-patient rheumatology clinic of the Hospital Xeral-Calde (Lugo, Spain) and 251 ethnically matched controls were studied. Patients and controls were genotyped by PCR-based techniques for a multiallelic (CCTTT)(n) repeat in the promoter region of the iNOS gene and for a T/C polymorphism at position -786 in the promoter region and a polymorphism in exon 7 (298Glu/Asp or 5557G/T) of the eNOS gene. RESULTS: No significant difference in allele or genotype frequencies for either polymorphism in the eNOS gene was observed between RA patients and controls. The overall iNOS CCTTT(n) allelic or genotypic distribution did not show statistical significant differences between RA patients and controls. Interestingly, when we stratified the iNOS alleles into short (8-11) and long (12-16) repeats, significant differences were observed between RA patients and controls (P = 0.021; odds ratio = 1.37, 95% confidence interval 1.04-1.81). Of note, individuals carrying two alleles with a repeat number less than 12 (fewer than 196 base pairs) exhibited a double risk of developing RA (P = 0.005, odds ratio 2.26, 95% confidence interval 1.25-4.08). CONCLUSIONS: Significant differences in the iNOS promoter polymorphism genotype frequency between northwest Spanish RA patients and controls suggest a potential role for this polymorphism in susceptibility to RA.
Assuntos
Artrite Reumatoide/genética , Óxido Nítrico Sintase/genética , Polimorfismo Genético/genética , Artrite Reumatoide/enzimologia , Frequência do Gene , Predisposição Genética para Doença/genética , Genótipo , Humanos , Repetições de Microssatélites/genética , Óxido Nítrico Sintase Tipo II , Óxido Nítrico Sintase Tipo III , Regiões Promotoras Genéticas , Fator Reumatoide/genéticaRESUMO
OBJECTIVE: E-selectin is expressed on cytokine-stimulated endothelial cells and plays an important role in leukocyte-endothelium interactions and inflammatory cell recruitment. An A/C polymorphism at position +561 in the E-selectin gene, which yields an amino acid exchange from serine to arginine at position 128 in the epidermal growth factor-like domain, has been described. We have assessed whether this bi-allelic polymorphism may be implicated in the clinical expression of erythema nodosum (EN) secondary to sarcoidosis. METHODS: Thirty-one patients with biopsy-proven erythema nodosum (EN) associated with sarcoidosis, 68 patients with biopsy-proven EN related to other etiologies and 66 healthy matched controls from the Lugo region of Northwest Spain were studied. Patients and controls were genotyped for the A/C polymorphism gene by PCR-restriction fragment length polymorphism. RESULTS: A significantly reduced frequency of the C mutant allele was observed in patients with EN secondary to sarcoidosis compared to controls (p = 0.019) and also compared to patients with EN unrelated to sarcoidosis (p = 0.028). This was also the case when the distribution of genotypes in patients with sarcoidosis was compared with that observed in patients with EN due to other etiologies (p = 0.028) and controls (p = 0.037). This was due to an absence in both C/A heterozygotes and C/C homozygotes in patients with EN secondary to sarcoidosis. CONCLUSIONS: The present study constitutes the first attempt to assess the influence of E-selectin polymorphism at position +561 in the development of sarcoidosis. The C allele at the +561 position of the E-selectin gene is associated with significantly reduced risk of developing sarcoidosis in patients with EN.